[go: up one dir, main page]

WO2025151586A1 - Système d'administration de médicament pour cannabinoïdes - Google Patents

Système d'administration de médicament pour cannabinoïdes

Info

Publication number
WO2025151586A1
WO2025151586A1 PCT/US2025/010871 US2025010871W WO2025151586A1 WO 2025151586 A1 WO2025151586 A1 WO 2025151586A1 US 2025010871 W US2025010871 W US 2025010871W WO 2025151586 A1 WO2025151586 A1 WO 2025151586A1
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoids
cannabinoid
powder
carrier liquid
cannabinoid infused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/010871
Other languages
English (en)
Inventor
Ronald Noble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T Rex 1 Corp
Original Assignee
T Rex 1 Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Rex 1 Corp filed Critical T Rex 1 Corp
Publication of WO2025151586A1 publication Critical patent/WO2025151586A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • the present invention relates in general to cannabinoids, and, more particularly, to novel methods and systems for producing cannabinoids with enhanced bioavailability for maximizing absorption when orally and/or topically administered.
  • CBD cannabidiol
  • Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation.
  • THC tetrahydrocannabinol
  • United States Patent Number 10,080,736 appears to disclose a cannabinoid-containing composition
  • a cannabinoid-containing composition comprising a plurality of droplets in an emulsion, wherein an individual droplet of said plurality has a size less than or equal to about 500 nanometers and comprises: (i) at least one cannabinoid compound; (ii) at least one terpene compound; and (iii) a compound that counteracts tetrahydrocannabinol (THC) intoxication, wherein the compound is pregnenolone, wherein said composition comprises (1 ) at least one terpene compound present in an amount of at least one microgram, and
  • composition comprising said plurality of droplets has a shelf half-life of at least 1 week, wherein said individual droplet has a THC content of more than 0% and less than 0.3% by weight, and wherein said at least one cannabinoid compound in said emulsion has a bioavailability of at least twice that of said at least one cannabinoid compound in nondroplet-encapsulated form.
  • United States Patent Number 8,222,292 appears to disclose oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.
  • the '292 patent teaches an oral pharmaceutical solution consisting essentially of: dronabinol, 30- 33% w/w water, about 50% w/w alcohol, 0.01 % w/w butylated hydroxylanisole (BHA) or 0.1 % w/w ethylenediaminetetraacetic acid (EDTA) and 5-21 % w/w co-solvent, having a combined total of 100%, wherein said co-solvent is selected from the group consisting of propylene glycol, polyethylene glycol and combinations thereof, and wherein said oral pharmaceutical solution is stable for at least eighteen months at room or refrigerated temperatures and has in vivo absorption variability of less than 50%.
  • United States Patent Application Publication Number 2021/0069103 appears to disclose self-emulsifying drug delivery systems that are used in the oral delivery of cannabinoids.
  • the cannabinoids are dissolved in an oily medium (e.g. medium chain triglycerides) together with at least one surfactant to improve dissolution, stability, and bioavailability.
  • an oral cannabinoid compositions for the treatment of neuropathic pain in a subject.
  • United States Patent Application Publication Number 2021/0059975 appears to disclose a particular water-dispersible solid formulation of a cannabinoid or a cannabis extract, wherein they are present in the form of a nanoemulsion, and upon dispersion in water said formulation produces nanoparticles (droplets of a submicron size) with an average size of up to about 500 nm.
  • United States Patent Application Publication Number 2019/0282502 appears to disclose a method of manufacturing a flowable and dispersible powder that includes solubilizing a lipophilic substance in a terpene to form a mixture and treating the mixture to form a nanoemulsion dispersed in an aqueous solution.
  • the aqueous solution includes at least one functional excipient.
  • the nanoemulsion is then spray dried, thereby evaporating first the aqueous portion and then the terpene to form a dry powder formed from solid particles comprising the lipophilic substance.
  • United States Patent Application Publication Number 2018/0271826 appears to disclose dry powders that comprise a cannabinoid, a polymer binding agent, a dispersing agent, and a bulking agent, and optionally an antioxidant, and are formed by carbon dioxide-assisted nebulization and drying in a flowing dry stream of gas.
  • the dry powders have an aerodynamic particle distribution effective for delivery by respiration into the lungs of a patient.
  • Methods of preparing a dry powder comprise subjecting a solution of a volatile component, a cannabinoid, a polymer binding agent, a dispersing agent, and a bulking agent, and optionally an antioxidant, to carbon dioxide-assisted nebulization, and drying droplets formed by the nebulization in a flowing dry gas stream to form a dry powder.
  • the dry powder has an aerodynamic particle distribution effective for delivery of the dry powder by respiration into a lung of a patient and/or exhibit increased bioavailability and/or storage stability of a cannabinoid.
  • the dry powder can be compressed into a wafer.
  • the '321 reference teaches a cannabinoid composition
  • a cannabinoid composition comprising: a cannabinoid preparation ranging from 0.1 % to 20% (w/w); at least one surfactant ranging from 5% to 50% (w/w); at least one co-solvent ranging from 10% to 70% (w/w); water ranging from 16% to 60% (w/w); and wherein the cannabinoid composition is capable of topical application.
  • the step of extracting includes the step of extracting cannabinoids from the biomass, wherein the extracted cannabinoids are free from solvent.
  • the step of associating the extracted cannabinoids with a carrier liquid includes the step of dissolving the extracted cannabinoids in the carrier liquid, such as a an edible lipid.
  • the step of associating the cannabinoid infused carrier powder with water includes the step of dissolving the cannabinoid infused carrier powder in water to form liposomes containing cannabinoids in an aqueous solution.
  • the cannabinoid infused carrier powder is associated with and/or dissolved into an ingestible polar solvent (e.g., water) to form liposomes containing cannabinoids in a solution.
  • an ingestible polar solvent e.g., water

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de préparation d'une solution contenant des cannabinoïdes, comprenant les étapes consistant à : (a) fournir une biomasse contenant des cannabinoïdes ; (b) extraire les cannabinoïdes de la biomasse, les cannabinoïdes extraits étant pratiquement exempts de solvant ; (c) associer les cannabinoïdes extraits à un liquide porteur pour former un liquide porteur infusé de cannabinoïdes ; (d) associer le liquide porteur infusé de cannabinoïdes à un solide ou une poudre pour former une poudre porteuse infusée de cannabinoïdes ; et (e) associer la poudre de support infusée de cannabinoïdes à de l'eau pour former des liposomes contenant des cannabinoïdes dans une solution aqueuse.
PCT/US2025/010871 2024-01-10 2025-01-09 Système d'administration de médicament pour cannabinoïdes Pending WO2025151586A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202418408754A 2024-01-10 2024-01-10
US18/408,754 2024-01-10

Publications (1)

Publication Number Publication Date
WO2025151586A1 true WO2025151586A1 (fr) 2025-07-17

Family

ID=96387520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/010871 Pending WO2025151586A1 (fr) 2024-01-10 2025-01-09 Système d'administration de médicament pour cannabinoïdes

Country Status (1)

Country Link
WO (1) WO2025151586A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016135621A1 (fr) * 2015-02-24 2016-09-01 Ross Franklin M Procédé pour amener de l'huile de cannabis concentrée à être stable, émulsifiable et sans saveur en vue de son utilisation dans des boissons chaudes, et huile de cannabis réduite en poudre ainsi obtenue
WO2019014631A1 (fr) * 2017-07-14 2019-01-17 5071, Inc. Compositions de cannabinoïdes et procédés de préparation associés

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016135621A1 (fr) * 2015-02-24 2016-09-01 Ross Franklin M Procédé pour amener de l'huile de cannabis concentrée à être stable, émulsifiable et sans saveur en vue de son utilisation dans des boissons chaudes, et huile de cannabis réduite en poudre ainsi obtenue
WO2019014631A1 (fr) * 2017-07-14 2019-01-17 5071, Inc. Compositions de cannabinoïdes et procédés de préparation associés

Similar Documents

Publication Publication Date Title
CN102341166B (zh) 分散组合物及分散组合物的制造方法
US9849108B2 (en) Composition with pharmacological effect for vaporizing and method
CN101579291B (zh) 一种白藜芦醇磷脂复合物纳米乳液及其制备方法与应用
US10933016B2 (en) Compositions and methods for oral administration of cannabinoids and terpenoids
JP2005512943A5 (fr)
RS66776B1 (sr) Razblažive formulacije kanabinoida i procesi za njihovu pripremu
WO2015068052A2 (fr) Formulations de terpène et de cannabinoïdes
US10596147B1 (en) Metered dose inhaler compositions, systems, and methods
JP7444995B2 (ja) 超微粒化合物およびその製造
US20220370379A1 (en) Cannabinoid-containing additive and method therefor
WO2022013854A1 (fr) Compositions cannabinoïdes orales
US20220183972A1 (en) Nanoemulsion hydrophobic substances
CN101088524A (zh) 黄芩天然活性成分的磷脂复合物及其制备方法和制剂
WO2025151586A1 (fr) Système d'administration de médicament pour cannabinoïdes
US11458092B2 (en) Composition with enhanced passenger molecule loading
EP3782608A1 (fr) Procédé d'amélioration de chargement de molécules de passagers
CN117883385A (zh) 一种含复方药的纳米脂质体及其制备方法和应用
CN101088523A (zh) 黄芩天然活性成分的固体脂质纳米粒及其制备方法和制剂
CN101147727A (zh) 莪术醇亚微乳及其制备方法和制剂
CN1951401A (zh) 蟾酥固体脂质纳米粒及其制备方法
Ganji et al. Formulation, excipient properties and pharmacological activities of catechin liposomes
US12011470B2 (en) Micelle preparations of full-spectrum hemp oil
Utami et al. Toxicity of self-nanoemulsifying drug delivery system formulation of Nigella sativa L. seed oil against adult Danio rerio
US11826320B2 (en) Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm
CN102988484A (zh) 黄芩天然活性成分的磷脂复合物及其制备方法和制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25739259

Country of ref document: EP

Kind code of ref document: A1